Founding Engineer

At Alleviate Health we’re building AI Agents that drastically accelerate clinical trials by autonomously communicating with patients to recruit them into trials and support them over years, pruning billions in excess spend. We’re solving the problem that keeps execs at the largest $100B+ Pharma companies up at night.

We bootstrapped to winning some of the largest enterprise accounts in the market and are seeing massive market pull. We’ve now raised a $4.3M seed round led by a16z and are hiring a world-class team to solve the largest problem in drug development and win one of the largest opportunities in AI – while slashing the time it takes to bring life-changing medicines to the patients who desperately need them.

Conducting a clinical trial is the most complex and broken, but also the most high‑stakes and capital intensive, problem of our era.

To bring a life-saving medicine from the lab bench to patients, pharma companies spend tens of billions a year for research sites to qualify & screen hundreds of thousands of patients and then to stay in contact with those patients over years. Approximately 80% of clinical trials are delayed due to problems with recruitment and between $600,000 and $8 million is lost for each day a trial is delayed.

This enormous, labor-intensive struggle of screening, recruitment, and retention of patients across thousands of small research sites in every single trial is the foundational bottleneck in clinical trials.

At Alleviate we've built SOTA AI Agents that autonomously recruit & retain patients in trials.

Currently, our AI agents conduct over 100,000 conversations every month by:

• Intelligently screening & routing patients to the right trials.

• Collecting necessary data for the trial from patients multiple times per week.

• Answering patients’ questions perfectly and supporting them 24/7 throughout the trial - reducing costly drop-offs.

• Continuously learning from each interaction to optimize performance.

Our team worked at a small research site for months to understand the problem deeply -- personally calling and speaking to patients -- and then bootstrapped to working with some of the largest clinical research organizations in the world and conducting over a 100k conversations per month.

1. Hypergrowth. We’re growing rapidly MoM (both within existing & new accounts). We’ve landed (and realized) multiple 6 figure deals. Our largest live contract has an annual value of >$350k.

2. Our win rate on commercial deals is >92%. We’re the market leading solution - we’ve never lost a deal to competitors and have actively poached multiple customers from competitors.

3. Our market is gigantic and immensely painful. We can’t mention their names publicly but have landed pilots with top 20 pharma(s) that will grow to $XM+/yr. Our pipeline grows organically due to customer fear of falling behind after hearing from our existing customers.

We’re now backed by Andreessen Horowitz and other investors like Jack Altman (Co-Founder of Lattice), Zach Weinberg (Co-Founder of Flatiron Health, the largest Pharma tech exit of all time), Ali Rowghani (Former CFO & COO of Twitter), Trey Holterman (CEO & Co-Founder of Tennr) and many others who’ve built category defining healthcare & pharma companies.

• Orchestrating a fleet of AI agents that coordinate patient recruitment across hundreds of clinical trials across North America (For now).

• Training a proprietary ML model that matches detailed patient profiles to trials using real-world outcomes to learn what actually qualifies and enrolls patients.

• Scaling LLMs across Voice, SMS, and email while keeping conversations consistent and personalized across all channels.

• Reverse engineering legacy healthcare systems that don’t have public APIs to integrate with trial sites’ existing tool stack.

We’re going after the largest problem in one of the largest markets in the world. We already replace tens of millions in excess spend and will replace billions of dollars of excess spend while slashing the time it takes to bring life-changing medicines to the patients who desperately need them.

We’re looking for exceptional founding engineers to help us realize this ambition. If you’re an engineer that finds this goal compelling, we'd love to talk.